Canine Acetylcholinesterase ELISA , AChE
- Known as:
- Canine Acetylcholinesterase Enzyme-linked immunosorbent assay test , AChE
- Catalog number:
- E08A0712
- Category:
- -
- Supplier:
- Blue Gene Biotech
- Gene target:
- Canine Acetylcholinesterase ELISA AChE
Related genes to: Canine Acetylcholinesterase ELISA , AChE
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: Canine Acetylcholinesterase ELISA , AChE
Related articles to: Canine Acetylcholinesterase ELISA , AChE
- Fibromyalgia (FM) is a chronic widespread pain syndrome frequently accompanied by fatigue, cognitive dysfunction, psychological symptoms, and multiple somatic symptoms. Coronavirus disease 2019 (COVID-19) has affected millions worldwide; however, its long-term sequelae remain incompletely understood. - Source: PubMed
Publication date: 2026/08/07
Alhayali MustafaSalman SamiShahrori Mustafa AAhmed Shimal AyaAhmed Marafi JammaaAl-Mashhadani MarwahShukur ZainabAlfirtusi NoorAl-Obaidi Ahmed Dheyaa - This study aimed to investigate psychological need frustration as a predictor of sport injury anxiety among HIFT athletes, and to examine the roles of demographic and training-related variables in injury-related anxiety. - Source: PubMed
Publication date: 2026/08/07
Bozkuş UmutcanPancar ZarifeKaraca BurakDarendeli Muhammed KaanUlema Mustafa SencerÜneşi Nursel - Irritable bowel syndrome (IBS) is a chronic functional bowel disease and a common cause of gastroenterological referrals. This cross-sectional survey estimated the prevalence of Rome IV-defined IBS symptoms among adults residing in Saudi Arabia and examined their associations with sociodemographic characteristics, and self-reported symptoms of depression, anxiety, and stress. - Source: PubMed
Publication date: 2026/08/07
Baig MukhtiarAlhammad Mustafa AhmedAlghamdi Waleed AhmedAbualhamael Shahad AbduljalilAlzahrani Ali Hassan JaberAlharbi Abdulrahman AbdulmohsenAlhassan Khadijah JassimAlsagoor Dhafer MohammedAlyoubi Bandar HalilAlkaabi Turki AkramAlshuaibi Ammar AbdulkhaliqAlHarbi Rehaf FahadAlkhurayyif Ahmed Ibrahim - Endoscopic procedures increase the risk of endoscopy-related musculoskeletal disorders (ErMSD), with high prevalence reported internationally; however, Australian data are limited. This study aimed to determine the prevalence of ErMSD among Australian endoscopists and identify associated risk factors and protective behaviours. A national online survey of credentialled endoscopists collected data on demographics, procedure type and volume, pain and injury history, consequences (including treatment and work modification), and prevention practices. Eighty-one endoscopists (73.8% surgeons, 25.0% gastroenterologists) participated. Overall, 61.7% reported current (29.6%) or previous (32.1%) ErMSD. Common injury sites included the thumbs/hands, lumbar and cervical spine. Higher weekly colonoscopy volume was significantly associated with ErMSD ( = 0.01). Symptoms were frequently exacerbated during or after procedures (80.9%), with over half reporting impacts on activities outside work (51.1%) or requiring formal treatment (57.4%). ErMSD is prevalent among Australian endoscopists and is associated with procedural volume, highlighting the need for targeted prevention strategies. - Source: PubMed
Publication date: 2026/08/22
Devin JamesRajan VasantSzetoo WiyangMartin JasonHolland JustinDevereaux Benedict - BackgroundAnkylosing spondylitis is a chronic inflammatory disease that causes severe spinal pain and structural disability. Conventional nonbiologic treatments often fail to provide adequate disease control.ObjectiveTo evaluate the 12 month clinical efficacy and safety of subcutaneous golimumab compared with those of other drug therapies in Syrian patients with active ankylosing spondylitis.MethodsThis prospective multicenter cohort study evaluated 66 patients with active ankylosing spondylitis who completed the 12-month observational period. Thirty-three (n = 33) patients received monthly subcutaneous golimumab from study initiation and 33 (n = 33) received other standard drug regimens (nonsteroidal anti-inflammatory drugs/conventional disease-modifying antirheumatic drugs). Disease activity and functional impairment were measured with Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores using area under the curve and longitudinal mean trends. Adverse events were monitored throughout the study period.ResultsPatients treated with golimumab from study initiation demonstrated a rapid, profound clinical response. Mean Bath Ankylosing Spondylitis Disease Activity Index scores decreased considerably from 6.93 to 1.22 at 12 months, resulting in the transition of 87.9% of the cohort into the "low disease activity" category. Similarly, mean Bath Ankylosing Spondylitis Functional Index scores decreased from 5.42 to 1.07, with no patient exhibiting functional impairment at 6 months. Conversely, the other drug arm exhibited gradual declines, with 60.6% of the patients remaining in the "severe functional impairment" category at 12 months. Area under the curve analysis revealed highly significant therapeutic superiority of golimumab for both parameters 0.001). Golimumab was well tolerated with only mild, nonserious adverse event reported (upper respiratory infections, 6%), whereas patients in the other drug arm experienced peptic ulcers (6.1%) and elevated liver enzyme levels (3%).ConclusionIn a real-world clinical setting, initiating monthly subcutaneous golimumab achieved vastly superior 12-month efficacy and a favorable safety profile compared with other conventional drug regimens, rapidly reducing disease burden and restoring physical function in patients with active ankylosing spondylitis. - Source: PubMed
Publication date: 2026/08/21
Drie TasneemAlras AbdalrhmanAlfandi AbdullahAljabak Ibrahim MohamadKudsi Maysoun